The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
Maria-Grazia LazzaroniFrancesca MottaCampochiaro CorradoJeska DeVries-BouwstraMontserrat-Ixchel Gonzalez-PerezJorge Rojas-SerranoEric HachullaElisabetta ZanattaSimone BarsottiFederica FuriniKonstantinos TriantafylliasGiuseppina AbignanoMarie-Elise TruchetetGiacomo De LucaEllen De LangheRoger HesselstrandFrancesca IngegnoliEugenia BertoldoVanessa SmithSilvia Bellando-RandoneHadi PoormoghimEnrico ColomboAngela CeribelliAlessio FurloniStefania ZingarelliIlaria CavazzanaFranco FranceschiniFrancesco Del GaldoChristopher P DentonLorenzo CavagnaOliver DistlerYannick AllanorePaolo Airònull nullPublished in: Rheumatology (Oxford, England) (2021)
The analysis of the largest series of anti-PM/Scl+ SSc patients so far reported helps to delineate a specific clinical subset with muscle involvement, cutaneous DM, calcinosis and ILD characterized by a good functional outcome. SRC and malignancies do not seem to be part of this syndrome.
Keyphrases
- systemic sclerosis
- interstitial lung disease
- end stage renal disease
- particulate matter
- air pollution
- newly diagnosed
- ejection fraction
- chronic kidney disease
- heavy metals
- skeletal muscle
- peritoneal dialysis
- prognostic factors
- rheumatoid arthritis
- type diabetes
- risk assessment
- case report
- idiopathic pulmonary fibrosis
- water soluble
- weight loss